Simmons Bank’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.26M | Sell |
8,233
-80
| -1% | -$12.3K | 0.08% | 178 |
|
|
2025
Q4 | $1.15M | Sell |
8,313
-400
| -5% | -$52.4K | 0.08% | 176 |
|
|
2025
Q3 | $1.12M | Sell |
8,713
-16
| -0.2% | -$1.95K | 0.07% | 178 |
|
|
2025
Q2 | $1.06M | Sell |
8,729
-445
| -5% | -$50.2K | 0.08% | 181 |
|
|
2025
Q1 | $1.02M | Sell |
9,174
-38
| -0.4% | -$4.04K | 0.08% | 179 |
|
|
2024
Q4 | $896K | Sell |
9,212
-75
| -0.8% | -$8K | 0.07% | 190 |
|
|
2024
Q3 | $1.07M | Sell |
9,287
-232
| -2% | -$26.3K | 0.08% | 177 |
|
|
2024
Q2 | $1.01M | Sell |
9,519
-205
| -2% | -$20.6K | 0.08% | 178 |
|
|
2024
Q1 | $941K | Buy |
9,724
+12
| +0.1% | +$1.23K | 0.07% | 189 |
|
|
2023
Q4 | $981K | Hold |
9,712
| – | – | 0.08% | 182 |
|
|
2023
Q3 | $989K | Sell |
9,712
-116
| -1% | -$11.8K | 0.09% | 179 |
|
|
2023
Q2 | $992K | Sell |
9,828
-120
| -1% | -$12K | 0.08% | 180 |
|
|
2023
Q1 | $915K | Sell |
9,948
-388
| -4% | -$33.9K | 0.08% | 192 |
|
|
2022
Q4 | $938K | Sell |
10,336
-10
| -0.1% | -$842 | 0.08% | 190 |
|
|
2022
Q3 | $786K | Sell |
10,346
-580
| -5% | -$48.1K | 0.07% | 201 |
|
|
2022
Q2 | $923K | Sell |
10,926
-785
| -7% | -$68.9K | 0.08% | 199 |
|
|
2022
Q1 | $1.03M | Sell |
11,711
-212
| -2% | -$18.4K | 0.08% | 209 |
|
|
2021
Q4 | $1.04M | Sell |
11,923
-91
| -0.8% | -$7.56K | 0.07% | 202 |
|
|
2021
Q3 | $982K | Sell |
12,014
-333
| -3% | -$30K | 0.07% | 210 |
|
|
2021
Q2 | $1.13M | Sell |
12,347
-709
| -5% | -$63.1K | 0.08% | 200 |
|
|
2021
Q1 | $1.12M | Sell |
13,056
-459
| -3% | -$41.2K | 0.08% | 191 |
|
|
2020
Q4 | $1.28M | Sell |
13,515
-5,082
| -27% | -$444K | 0.1% | 168 |
|
|
2020
Q3 | $1.62M | Sell |
18,597
-939
| -5% | -$81.3K | 0.13% | 150 |
|
|
2020
Q2 | $1.71M | Buy |
19,536
+2,454
| +14% | +$212K | 0.14% | 140 |
|
|
2020
Q1 | $1.41M | Buy |
17,082
+4,401
| +35% | +$393K | 0.12% | 140 |
|
|
2019
Q4 | $1.2M | Sell |
12,681
-979
| -7% | -$87.8K | 0.11% | 163 |
|
|
2019
Q3 | $1.19M | Sell |
13,660
-106
| -0.8% | -$9.52K | 0.12% | 157 |
|
|
2019
Q2 | $1.26M | Sell |
13,766
-1,653
| -11% | -$140K | 0.12% | 151 |
|
|
2019
Q1 | $1.33M | Sell |
15,419
-47
| -0.3% | -$3.77K | 0.13% | 152 |
|
|
2018
Q4 | $1.19M | Sell |
15,466
-347
| -2% | -$27K | 0.13% | 143 |
|
|
2018
Q3 | $1.22M | Buy |
15,813
+424
| +3% | +$31.3K | 0.12% | 153 |
|
|
2018
Q2 | $1.04M | Hold |
15,389
| – | – | 0.09% | 168 |
|
|
2018
Q1 | $1.11M | Sell |
15,389
-334
| -2% | -$25.4K | 0.1% | 157 |
|
|
2017
Q4 | $1.18M | Sell |
15,723
-491
| -3% | -$37K | 0.12% | 139 |
|
|
2017
Q3 | $1.25M | Sell |
16,214
-251
| -2% | -$19K | 0.13% | 137 |
|
|
2017
Q2 | $1.23M | Sell |
16,465
-123
| -0.7% | -$8.72K | 0.14% | 137 |
|
|
2017
Q1 | $1.1M | Sell |
16,588
-318
| -2% | -$21.2K | 0.12% | 132 |
|
|
2016
Q4 | $1.1M | Sell |
16,906
-765
| -4% | -$49.6K | 0.12% | 145 |
|
|
2016
Q3 | $1.25M | Sell |
17,671
-10
| -0.1% | -$729 | 0.14% | 130 |
|
|
2016
Q2 | $1.31M | Buy |
17,681
+64
| +0.4% | +$4.42K | 0.15% | 128 |
|
|
2016
Q1 | $1.14M | Buy |
+17,617
| New | +$1.2M | 0.13% | 140 |
|
Other funds holding NVS
Simmons Bank's NVS Position: Q1 2026 in Review
Simmons Bank reduced its Novartis (NVS) stake by 0.96% in Q1 2026, selling an estimated $12.3K and leaving 8,233 shares worth $1.26M. The position accounts for 0.08% of the portfolio, ranked #178.
Simmons Bank first reported a position in NVS in Q1 2016 and has held it in 41 quarters since. The position peaked at $1.71M in Q2 2020. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Simmons Bank held 8,233 shares of Novartis worth $1.26M as of Q1 2026.
- Simmons Bank sold 80 Novartis shares in Q1 2026, an estimated $12.3K.
- Novartis made up 0.08% of Simmons Bank's portfolio in Q1 2026, its #178 holding.
- Simmons Bank first reported a position in Novartis in Q1 2016 and has held it in 41 quarters since.
- Simmons Bank's Novartis position peaked at $1.71M in Q2 2020.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Simmons Bank's 13F filing for Q1 2026, filed 23 Apr 2026.